Ethical testing of experimental ebola treatments

JAMA - Journal of the American Medical Association

Volumn 313, Issue 4, 2015, Pages 421-

  Folayan, Morenike Oluwatoyin ^a   Haire, Bridget ^b   Peterson, Kristin ^c  

^a OBAFEMI AWOLOWO UNIVERSITY   (Nigeria)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT;

COMPASSIONATE USE; CONTROL GROUP; DRUG APPROVAL; DRUG EFFICACY; EBOLA HEMORRHAGIC FEVER; HEALTH CARE ACCESS; HEALTH CARE DELIVERY; HEALTH CARE SYSTEM; HEALTH PROGRAM; HUMAN; LETTER; MEDICAL DECISION MAKING; MEDICAL RESEARCH; METHODOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESEARCH ETHICS; SURVIVAL RATE; HEMORRHAGIC FEVER, EBOLA;

HEMORRHAGIC FEVER, EBOLA; HUMANS;

EID: 84921714261     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2014.17256     Document Type: Letter

References (4)

1. Joffe S. Evaluating novel therapies during the Ebola epidemic. JAMA. 2014; 312(13):1299-1300.
2. Persad G,Wertheimer A, Emanuel EJ. Principles for allocation of scarce medical interventions. Lancet. 2009;373(9661):423-431.
3. RossW. Ebola crisis: doctors in Liberia "recovering after taking ZMapp." http: //www.bbc.com/news/world-africa-28860204. Accessed September 1, 2014.
4. Maurice J.WHOmeeting chooses untried interventions to defeat Ebola. Lancet. 2014;384(9948):e45-e46.